A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms PARAMETER
- Sponsors Novartis Pharmaceuticals
- 23 Aug 2017 Planned locations also included Brazil as per European Clinical Trials Database.
- 05 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.